September 19, 2017
BioCardia Announces Publication of 12-Month Results from Phase II TRIDENT Clinical Trial That Shows Positive Safety Profile for Allogeneic Bone Marrow Stem Cells Delivered with Helix Transendocardial Delivery System
September 15, 2017
BioCardia’s CardiAMP Heart Failure Trial Design to be Presented at Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine
September 7, 2017
BioCardia receives US Patent covering a method of preparing and characterizing mesenchymal cells, providing further protection to CardiALLO cell therapy program
July 26, 2017
BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial
May 24, 2017
Study Shows Helix Transendocardial Delivery System Enables Greater Myocardial Retention of Stem Cell Therapy
April 26, 2017
BioCardia to Present at the 5th Annual Cell & Gene Investor Day
February 28, 2017
Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial
|
We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells.
These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
|
